Risperidone long-acting injection

Expert Review of Neurotherapeutics

Volumn 3, Issue 4, 2003, Pages 435-446

  Chue, Pierre ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Depot; Long activating atypical antipsychotics; Microspheres; Risperidone

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAMAZEPINE; DOPAMINE RECEPTOR STIMULATING AGENT; FLUOXETINE; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; LEVODOPA; LITHIUM; LONG ACTING DRUG; MICROSPHERE; OLANZAPINE; PHENOTHIAZINE DERIVATIVE; RISPERIDONE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID; ZUCLOPENTHIXOL;

ANXIETY; APATHY; ATTENTION DEFICIT DISORDER; BODY WEIGHT DISORDER; CLINICAL TRIAL; DEPRESSION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG COST; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG OVERDOSE; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; HEADACHE; HIGH RISK POPULATION; HUMAN; HYPERPROLACTINEMIA; HYPOTENSION; INJECTION; INJECTION PAIN; LENGTH OF STAY; LEUKOCYTOSIS; LIVER TOXICITY; NERVOUSNESS; NONHUMAN; PRURITUS; PSYCHOSIS; QUALITY OF LIFE; RASH; RESOURCE MANAGEMENT; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; SLEEP DISORDER; SUSTAINED RELEASE PREPARATION; SYNCOPE; TOXICITY TESTING; VISUAL DISORDER; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 0037700982     PISSN: 14737175     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737175.3.4.435     Document Type: Review

References (50)

1. Watt DC, Karz K, Shepherd M. The natural history of schizophrenia: a 5-year prospective follow-up of a representative sample of schizophrenics by means of a standardized clinical and social assessment. Psychol. Med. 13, 663-670 (1983).
2. Robinson D, Woerner MG, Alvir JM et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch. Gen. Psych. 56, 241-247 (1999).
3. Gaebel W, Pietzcker A. Multidimensional study of the outcome of schizophrenic patients 1 year after clinic discharge. Predictors and influence of neuroleptic treatment. Eur. Arch. Psych. Neurol. Sci. 235, 45-52 (1985).
4. Kane JM. Schizophrenia. N. Engl. J. Med. 334, 34-41 (1996).
5. Davis JM. Maintenance therapy and the natural course of schizophrenia. J. Clin. Psych. 46, 18-21 (1985).
6. Gitlin M, Nuechterlein K, Subotnik K et al. Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia. Am. J. Psychiatry 158, 1835-1842 (2001).
7. Misdrahi D, Llorca PM, Lancon C, Bayle FJ. Compliance in schizophrenia: predictive factors, therapeutical considerations and research implications. Encephale 28, 266-272 (2002). Very current review of compliance and impact on treatment.
8. Lieberman JA, Alvir JM, Koreen A et al. Psychobiologic correlates of treatment response in schizophrenia. Neuropsychopharmacology 14, S13-S21 (1996).
9. Davies LM, Drummond MF. Economics and schizophrenia: the real cost. Br. J. Psychiatry 25, 18-21 (1994).
10. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr. Bull. 21(3), 419-429 (1995).
11. Babiker IE. Noncompliance in schizophrenia. Psychiatr. Dev. 4, 329-337 (1986).
12. Almond S, O'Donnell O. Cost analysis of the treatment of schizophrenia in the UK. A simulation model comparing olanzapine, risperidone and haloperidol. Pharmaco Economics 17, 383-389 (2000).
13. Kane JM, Aguglia E, Altamura AC et al. Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference, Siena, Italy. Eur. Neuropsychopharmacol. 8, 55-66 (1998).
14. Walburn J, Gray R, Gournay K, Quraishi S, David AS. Systematic review of patient and nurse attitudes to depot antipsychotic medication. Br. J. Psychiatry 179, 300-307 (2001).
15. Janssen Pharmaceutica NV. Data on file. October 2001.
16. Davis JM, Matalon L, Watanabe MD, Blake L, Metalon L. Depot antipsychotic drugs. Place in therapy. Drugs 47, 741-773 (1994).
17. Adams CE, Fenton MK, Quraishi S, David AS. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br. J. Psychiatry 179, 290-299 (2001).
18. Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N. Engl. J. Med. 346, 16-22 (2002). Landmark study demonstrating the effectiveness of an atypical antipsychotic in relapse prevention.
19. Love RC, Conley RR, Kelly DI, et al. Rehospitalization rates with the atypical antipsychotics in the Maryland mental health system. Schizophr. Res. 36, 345 (1999).
20. Moore DB, Kelly DL, Sherr JD, Love RC, Conley RR. Rehospitalization rates for depot antipsychotics and pharmacoeconomic implications: comparison with risperidone. Am. J. Health Syst. Pharm. 55, S17-S19 (1998).
21. Turner M. Long-acting injectable risperidone for schizophrenia. Future Prescriber 3(1), (2002).
22. Safarti Y, Olivier V, Bouhassira M. The use of new antipsychotics during treatment with schizoprenia - a European enquiry. L'Encephale 25, 658-666 (1999).
23. Lasser RA, Ramstack JM, Grandolfi GP, Mannaert E, D'Hoore P. Long-acting risperidone (Risperdal Consta™): manufacture using Medisorb® microsphere technology, pharmacokinetics, and injection-site assessments. Presented at the 16th Annual Convention of the American Psychiatric Nursing Association, Oct 3-9, TX, USA (2002).
24. Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors. Life Sci. 68, 29-39 (2000).
25. Leysen JE, Janssen PM, Megens AA, Schotte A. Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J. Clin. Psychiatry 55, 5-12 (1994).
26. Summary of Product Characteristics. Risperdal Consta™. Risperidone long-acting injection. Janssen-Cilag Ltd, NY, USA (2002).
27. Eerdekens M, Fleischhacker WW, Xie Y et al. Long-term safety and efficacy of Risperdal Consta™, the long-acting injection formulation of risperidone. Presented at the XXIII CINP Congress, June 23-27, Montreal, Canada (2002).
28. Bloch Y, Mendlovic S, Strupinsky S, Altshuler A, Fennig S, Ratzoni G. Injections of depot antipsychotic medications in patients suffering from schizophrenia: do they hurt? J. Clin. Psychiatry 62, 855-858 (2001).
29. Kane J, Eerdekens M, Keith S, Lesem M, Karcher K, Lindenmayer J-P. Efficacy and safety of a novel long-acting risperidone microspheres formulation. Presented at the 11th Biennial Winter Workshop on Schizophrenia, February 24-March 1, Davos, Switzerland (2002).
30. Chue P, Eerdekens M, Augustyns I, Lachaux B, Molcan P, Eriksson L, Pretorius H, David A. Efficacy and safety of long-acting risperidone microspheres and risperidone oral tablets. Presented at the 11th Biennial Winter Workshop on Schizophrenia, February 24-March 1, Davos, Switzerland (2002).
31. Chue P, Devos E, Duchesne I, Leal A, Mehnert A. One-year hospitalization rates in patients with schizophrenia during long-term treatment with long-acting risperidone. Presented at The 7th Annual Meeting of the International Society for Pharmacoeconomic and Outcomes Research, May 19-22, Arlington, VA, USA (2002).
32. Llorca P-M, Devos E, Eerdekens M, Duchesne I, Leal A, Mehnert A. Rehospitalization rates with long-acting risperidone injection are lower than those reported for other antipsychotics. Presented at the XXIII CINP Congress, June 23-27, Montreal, Canada (2002).
33. Rabinowitz J, Lichtenberg P, Kaplan Z, Mark M, Nahon D, Davidson M. Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics. Am. J. Psychiatry 158, 266-269 (2001).
34. Conley RR, Love RC, Kelly DL, Bartko JJ. Rehospitalization rates of patients recently discharged on a regimen of risperidone or dozapine. Am. J. Psychiatry 156, 863-868 (1999).
35. Hogarty GE, Schooler NR, Ulrich R, Mussare F, Ferro P, Herron E. Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride. Arch. Gen. Psych. 36, 1283-1294 (1979).
36. Remington G, Devos E, Eerdekens M, Duchesne I, Leal A, Mehnert A. Treatment with long-acting risperidone injection reduces healthcare resource use. Presented at the XXIII CINP Congress, June 23-27, Montreal, Canada (2002).
37. Glazer WM, Ereshefsky L. A pharmacoeconomic model of outpatient antipsychotic therapy in revolving door schizophrenic patients. Clin. Psych. 57, 337-345 (1996).
38. Chouinard G, Albright PS. Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol. J. Clin. Psychopharmacol. 17, 298-307 (1997).
39. Nasrallah H, Duchesne I, Mehnert A, Janagap C. Long-acting risperidone improves quality of life. Presented at the XXIII CINP Congress, June 23-27, Montreal, Canada (2002).
40. Freyberger HJ, Eerdekens M, Duchesne I, Mehnert A, Rabinowitz J. Patient satisfaction with their medication during long-term treatment with long-acting risperidone injection. Presented at the XXIII CINP Congress, June 23-27, Montreal, Canada (2002).
41. Kelleher JP, Centorrino F, Albert J, Baldessarini RJ. Advances in atypical antipsychotics for the treatment of schizophrenia. CNS Drugs 16, 249-261 (2002).
42. Cramer JA, Rosenheck R. Compliance with medication regimens for mental and physical disorders. Psychiatr. Serv. 49, 196-201 (1998).
43. Oehl M, Hummer M, Fleischhacker WW. Compliance with antipsychotic treatment. Acta Psychiatr. Scand. 102, 83-86 (2000).
44. Schooler NR, Keith SJ, Severe JB et al. Relapse and rehospitalization during maintenance treatment of schizophrenia. The effects of dose reduction and family treatment. Arch. Gen. Psych. 54, 453-463 (1997).
45. Gaebel W, Janner M, Frommann N et al. First verses multiple episode schizophrenia: two-year outcome of intermittent and maintenance medication strategies. Schizophr. Res. 53, 145-159 (2002).
46. Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J. Clin. Psych. 58, 538-546 (1997).
47. Patel MX, Nikolaou V, David AS. Psychiatrists' attitudes to maintenance medication for patients with schizophrenia. Psychol. Med. 33, 83-89 (2003). Interesting study illustrating physicians' perspectives to treatment.
48. Peuskens J. Switching approach in the management of schizophrenia patients. Int. Clin. Psychopharmacol. 15(Suppl. 4), S15-S19 (2000).
49. Hay J. Complications at site of injection of depot neuroleptics. Br. Med J. 12, 421 (1995).
50. Hogarty GE, Ulrich RF. The limitations of antipsychotic medication on schizophrenia relapse and adjustment and the contributions of psychosocial treatment. J. Psychiatr. Res. 32, 243-250 (1998).